Peter C. Enzinger

26.7k citations
151 papers · 9.2k · 3 hit papers · h-index 40

Impact in

  • Oncology top 0.5%
    • Pancreatic and Hepatic Oncology Research
    • Lung Cancer Research Studies
    • Cancer Immunotherapy and Biomarkers
  • Hepatology top 1%
    • Hepatocellular Carcinoma Treatment and Prognosis

Papers in

    • Gastric Cancer Management and Outcomes 56
    • Lung Cancer Treatments and Mutations 19
    • Colorectal Cancer Treatments and Studies 30
    • Cancer Immunotherapy and Biomarkers 19
    • Pancreatic and Hepatic Oncology Research 15

Peter C. Enzinger

141 papers receiving 9.0k citations

Peter C. Enzinger's Hit Papers

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial 2023 · 407 citations
4070+7+15Years since publication50010001.5k2.0k

Peers

Peter C. Enzinger
Comparison fields: 5 of 111
  • Oncology 3.4k
  • Hepatology 656
  • Pulmonary and Respiratory Medicine 2.3k
  • Gastroenterology 391
  • Surgery 2.9k
Replace Rosine Guimbaud with:
Rosine Guimbaud France
Maria Di Bartolomeo Italy
Robert R. McWilliams United States
Mark M. Zalupski United States
Antoine Adenis France
Mark Bloomston United States
Tarek Sahmoud Belgium
Young Suk Park South Korea
Lawrence S. Blaszkowsky United States
Jörg T. Hartmann Germany
Peter C. Enzinger relative to Rosine Guimbaud France Rosine Guimbaud's profile →
Citations per field
00.5×1.5×2.2×
Rosine Guimbaud · 1×
Citations per year

Countries citing papers authored by Peter C. Enzinger

Since Specialization
Citations

This map shows the geographic impact of Peter C. Enzinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter C. Enzinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter C. Enzinger more than expected).

Fields of papers citing papers by Peter C. Enzinger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter C. Enzinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter C. Enzinger. The network helps show where Peter C. Enzinger may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter C. Enzinger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter C. Enzinger Line = papers co-authored together Peter C. Enzinger links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 151 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Esophageal Cancer
Hit paper breakdown →
20032188
2 2006411
3
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
Hit paper breakdown →
2023407
4 2009375
5
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
Hit paper breakdown →
2018371
6 2006320
7 2014302
8 2008301
9 2008252
10 2009239
11 2012226
12 1999217
13 2007203
14 2019163
15 2006151
16 2007135
17 2019129
18 2005128
19 2014123
20
Chemotherapy in esophageal cancer.
1999120

About Peter C. Enzinger

Peter C. Enzinger is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Molecular Biology and Pathology and Forensic Medicine, having authored 151 papers that have together received 9.2k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (56 papers), Esophageal Cancer Research and Treatment (43 papers), Colorectal Cancer Treatments and Studies (30 papers), Cancer Immunotherapy and Biomarkers (19 papers), Lung Cancer Treatments and Mutations (19 papers), Pancreatic and Hepatic Oncology Research (15 papers), Gastrointestinal Tumor Research and Treatment (9 papers) and Barrier Structure and Function Studies (8 papers). The work is most often cited by research in Oncology (3.4k citations), Hepatology (656 citations), Pulmonary and Respiratory Medicine (2.3k citations), Gastroenterology (391 citations) and Surgery (2.9k citations). Peter C. Enzinger has collaborated with scholars based in United States, South Korea and Japan. Frequent co-authors include Robert J. Mayer, Charles S. Fuchs, Jeffrey W. Clark, David P. Ryan, Jeffrey A. Meyerhardt, Matthew H. Kulke, Keith Stuart, Lawrence S. Blaszkowsky, Andrew X. Zhu and Alona Muzikansky. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, The Oncologist, Future Oncology and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact